Amylyx Pharmaceuticals annual depreciation and amortization
2021
2022
2023
2024
2025
Amylyx Pharmaceuticals Depreciation & Amortization Growth & History (AMLX)
Amylyx Pharmaceuticals's depreciation and amortization was $525,000 for fiscal 2025.
View full Amylyx Pharmaceuticals company overviewAmylyx Pharmaceuticals annual depreciation and amortization history
| Fiscal year | Period ended | Depreciation and amortization | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $525,000 | −$379,000 | −41.92% |
| 2024 | 2024-12-31 | $904,000 | −$184,000 | −16.91% |
| 2023 | 2023-12-31 | $1.1M | $601,000 | +123.41% |
| 2022 | 2022-12-31 | $487,000 | $435,000 | +836.54% |
| 2021 | 2021-12-31 | $52,000 | — | — |
Amylyx Pharmaceuticals quarterly depreciation and amortization
Q1.21
Q2.21
Q3.21
Q1.22
Q2.22
Q3.22
Q1.23
Q2.23
Q3.23
Q1.24
Q2.24
Q3.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Depreciation and amortization | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $43,000 | −$98,000 | −69.50% |
| Q1 2026 | 2026-03-31 | $98,000 | −$58,000 | −37.18% |
| Q4 2025 | 2025-12-31 | $108,000 | — | — |
| Q3 2025 | 2025-09-30 | $120,000 | −$101,000 | −45.70% |
| Q2 2025 | 2025-06-30 | $141,000 | −$67,000 | −32.21% |
| Q1 2025 | 2025-03-31 | $156,000 | −$159,000 | −50.48% |
| Q3 2024 | 2024-09-30 | $221,000 | −$81,000 | −26.82% |
| Q2 2024 · Jun 30 | 2024-06-30 | $208,000 | −$73,000 | −25.98% |
| Q1 2024 | 2024-03-31 | $315,000 | $111,000 | +54.41% |
| Q3 2023 | 2023-09-30 | $302,000 | $137,000 | +83.03% |
| Q2 2023 | 2023-06-30 | $281,000 | $176,000 | +167.62% |
| Q1 2023 | 2023-03-31 | $204,000 | $169,000 | +482.86% |
| Q3 2022 | 2022-09-30 | $165,000 | $155,000 | +1550.00% |
| Q2 2022 | 2022-06-30 | $105,000 | $95,000 | +950.00% |
| Q1 2022 | 2022-03-31 | $35,000 | $25,000 | +250.00% |
| Q3 2021 | 2021-09-30 | $10,000 | — | — |
| Q2 2021 | 2021-06-30 | $10,000 | — | — |
| Q1 2021 | 2021-03-31 | $10,000 | — | — |
Amylyx Pharmaceuticals depreciation and amortization trends
Between the periods ended 2021-12-31 and 2025-12-31, Amylyx Pharmaceuticals's depreciation and amortization increased from $52,000 to $525,000, a change of $473,000. The latest reported quarter, Q2 2026, shows $43,000.
About the metric
What depreciation and amortization mean
Depreciation and amortization allocate the cost of tangible and intangible assets over their useful lives. These non-cash expenses reduce reported earnings and are commonly added back when calculating EBITDA and operating cash flow.
Calculation and source
Reported depreciation and amortization
TickerStat uses a combined depreciation and amortization value when reported. If a company reports the two components separately for an aligned period, they are added together without duplicating overlapping facts. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Amylyx Pharmaceuticals source filings ↗